公开(公告)号：US20170298361A1

公开(公告)日：2017-10-19

申请号：US15516405

申请日：2015-10-01

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef SHAUL ,  Rom David KESHET ,  Nina REUVEN

IPC: C12N15/113 ,  A61K31/506 ,  A61K31/553

CPC classification number: C12N15/1137 ,  A61K31/506 ,  A61K31/553 ,  C12N2310/14 ,  C12N2310/531

Abstract: Use of agents that down-regulates an amount and/or activity of Abelson murine leukemia viral oncogene homolog 1 (c-Abl) or checkpoint kinase 1 (Chk1) in the production of a medicament for treating obesity are disclosed.

公开(公告)号：US20160008390A1

公开(公告)日：2016-01-14

申请号：US14866957

申请日：2015-09-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef SHAUL ,  Peter Tsvetkov ,  Julia Adler

IPC: A61K31/713 ,  C12N15/113 ,  G01N33/50

CPC classification number: C12N15/1137 ,  A61K31/713 ,  C12N15/1135 ,  C12N2310/14 ,  C12Q1/025 ,  C12Q1/68 ,  G01N33/5011 ,  G01N2333/4703 ,  G01N2500/04 ,  G01N2500/10

Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.

Abstract translation: 公开了一种治疗癌症的方法。 该方法包括向受试者施用治疗有效量的药物组合物，其包含诱导26S蛋白酶体复合体解离成20S组分和19S组分从而抑制26S蛋白酶体活性的试剂，其中所述药剂没有 化疗剂。

公开(公告)号：US20170175127A1

公开(公告)日：2017-06-22

申请号：US15442784

申请日：2017-02-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef SHAUL ,  Peter TSVETKOV ,  Julia ADLER

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  A61K31/713 ,  C12N15/1135 ,  C12N2310/14 ,  C12Q1/025 ,  C12Q1/68 ,  G01N33/5011 ,  G01N2333/4703 ,  G01N2500/04 ,  G01N2500/10

Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.

公开(公告)号：US20230313173A1

公开(公告)日：2023-10-05

申请号：US17787977

申请日：2020-12-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef SHAUL ,  Nina REUVEN

IPC: C12N15/10 ,  C12N9/22 ,  C12N15/11 ,  C12N5/071 ,  C12N15/113

CPC classification number: C12N15/102 ,  C12N9/22 ,  C12N15/11 ,  C12N5/0686 ,  C12N15/113 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2310/14

Abstract: Kits and methods for selecting a cell harboring a genome-editing event at a target sequence of interest are disclosed. One such kit comprises:



(i) a first DNA editing agent for specifically introducing a mutation into a first gene so as to generate a first selection marker which imparts resistance to a selection agent, wherein the target sequence of interest the said first gene are distinct; and
(ii) the selection agent; and/or
(iii) a second DNA editing agent for specifically introducing a mutation into the first gene, wherein the mutation disrupts selection marker activity of the first selection marker.

公开(公告)号：US20210115092A1

公开(公告)日：2021-04-22

申请号：US17254932

申请日：2019-06-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef SHAUL ,  Nina REUVEN

IPC: C07K14/005 ,  C12N9/22 ,  C12N7/00 ,  C12N15/11 ,  A61K38/46 ,  A61K31/7088 ,  C12N15/90

Abstract: A recombinant system for improving genome editing via homologous recombination is disclosed. The system comprising a first nucleic acid sequence encoding a DNA editing agent having a double strand DNA cutting activity and a second nucleic acid sequence encoding a polypeptide capable of increasing homologous recombination in a target cell.